Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin

Blood Adv. 2018 Jul 10;2(13):1628-1632. doi: 10.1182/bloodadvances.2018015743.

Kristian Reckzeh^{1

2

3}, Hüsün Kizilkaya^{1

2}, Alexandra Søgaard Helbo^{1

2}, Montserrat Estruch Alrich^{1

2}, André Gundersen Deslauriers^{1

2

4

5}, Amit Grover⁶, Nicolas Rapin^{1

2

7}, Fazila Asmar⁸, Kirsten Grønbæk^{2

8}, Bo Porse^{1

2

3}, Niels Borregaard⁸, Dietmar Vestweber⁹, Claus Nerlov⁶, Kim Theilgaard-Mönch^{1

2

3

8}

¹ Finsen Laboratory, Rigshospitalet, Faculty of Health and Medical Sciences.
² Biotech Research and Innovation Center, Faculty of Health and Medical Sciences.
³ Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
⁴ Department of Epidemiology and Statistics, Memorial Sloan Kettering Cancer Center, New York, NY.
⁵ Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
⁶ MRC Molecular Hematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
⁷ Bioinformatics Centre, Department of Biology, and.
⁸ Department of Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; and.
⁹ Max Planck Institute for Molecular Biomedicine, University of Münster, Münster, Germany.

Abstract

EMCN is a novel marker of human HSCs.
EMCN is a more specific marker of HSCs than CD34 as it can discriminate HSCs from lineage-committed HPCs.